Study on the Health Economic Burden of Alzheimer's Disease in China

Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.

Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD. 2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction. 4.Participants or their legal representatives sign informed consent. Exclusion criteria 1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2). 2. Presence of mental or neurological developmental delay. 3. Presence of other known conditions that may cause cognitive impairment. 4. Diagnosis of a disease that prevents completion of cognitive assessments. 5. Refusal to sign informed consent at baseline.